What's in the Parkinson's Pipeline?

Tuesday, April 20, 2010
01:00 PM to 02:00 PM
EDT

When will there be new therapies for Parkinson’s?  Are scientists studying new ways to treat it?  To find out, view this one-hour PD ExpertBriefing, led by David G. Standaert, M.D., Ph.D., of the University of Alabama at Birmingham. 

Learning Objectives: 
  • Provide an understanding of the “pipeline," e.g., introduce the concepts of target identification and validation, drug development  and clinical trials
  • Review recently approved medications for Parkinson’s
  • Assess short-term expectations for the pipeline – potential new drugs for Parkinson’s that are already under investigation in clinical trials
  • Discuss long-term plans for the pipeline – potential drugs and approaches for treatment not yet in clinical trials
Faculty: 
David G. Standaert , M.D., Ph.D. , Director, Division of Movement Disorders, Director, American Parkinson Disease Association Advanced Center for Parkinson Research at UAB, and Director, Center for Neurodegeneration and Experimental Therapeutics

 

Dr. Standaert sees patients in a weekly clinic and oversees many clinical trials for new treatments of Parkinson's disease.  His research laboratory works on understanding both the root causes of Parkinson’s disease as well as the origin of the disabling symptoms that appear after long term treatment of the disease.  Recently, his group has focused on approaches to reducing the toxicity of synuclein in animal models of Parkinson's disease, and the role of neuroinflammatory reactions in disease progression.

Dr. Standaert previously served on the faculty of Massachusetts General Hospital (MG) as Director of the MGH/MIT Udall Center of Excellence in Parkinson’s Disease Research and as a Chair of the MGH Institutional Review Board (IRB).  He graduated from Harvard College and received his M.D. and Ph.D. degrees from Washington University in St. Louis.  He completed a one-year internship in Medicine followed by a three-year residency in Neurology at the University of Pennsylvania.  He was appointed as a Howard Hughes Medical Institute Physician Research Fellow, and completed a three-year research and clinical fellowship in Neurology (Movement Disorders) at Harvard Medical School and Massachusetts General Hospital.

He is a member of the Scientific Advisory Boards of the Michael J. Fox Foundation for Parkinson Research, the American Parkinson Disease Association and the Bachmann-Strauss Dystonia and Parkinson Foundation.

Questions? CEUs?

If you have questions about how to join this PD ExpertBriefing, by phone or online, please see our PD ExpertBriefing FAQ.

Are you a health care professional seeking continuing education units? CEUs are provided via PDF’s sponsorship of the American Society on Aging. When registering for this PD ExpertBriefing, please be sure to indicate interest in CEUs. Health professionals have 30 days in which to view the live or recorded seminar and apply for CEUs. It may take an additional 30 days to process CEUs.

Other Seminars

Browse our library of past seminars and watch them at any time to learn more about nutrition, the PD pipeline and other topics.

This series has been made possible by educational grants from AbbVie, Inc., Sunovion and Lundbeck LLC.

It is designed in collaboration with Dallas Area Parkinsonism Society (DAPS); Houston Area Parkinson Society (HAPS); Michigan Parkinson Foundation (MPF); the Neuro Challenge Foundation (NCF); Parkinson Association of the Carolinas (PAC); Parkinson Association of the Rockies (PAR); Parkinson's Association (PA) and Parkinson Support Center of Kentuckiana (PSCKY).